FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

FOCUS ON RESEARCH Previous Volume 358:2664-2665 June 19, 2008 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Hunder, N. N. Related Article by Finn, O. J. PubMed Citation

In 1987, an editorial accompanying a report on the use of high-dose interleukin-2 therapy for cancer asked whether the field of immunotherapy was at "the beginning of the end" or "the end of the beginning."¹ In retrospect, I would say it was at the "beginning of the beginning." Have we made progress since then? Finn, in her review of tumor immunology in this issue of the Journal (pages 2704–2715), answers emphatically in the affirmative, and the report by Hunder et al., also in this issue (pages 2698–2703), underscores the remarkable potential of the immune system to eradicate cancer, even when . . . [Full Text of this Article]

Source Information

Dr. Weiner is director of the Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC.

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.